CytomX Therapeutics, Inc.
NASDAQ:CTMX
0.86 (USD) • At close February 4, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | CytomX Therapeutics, Inc. |
Symbool | CTMX |
Munteenheid | USD |
Prijs | 0.864 |
Beurswaarde | 67,607,864 |
Dividendpercentage | 0% |
52-weken bereik | 0.79 - 5.85 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Sean A. McCarthy D.Phil., DPHIL |
Website | https://www.cytomx.com |
An error occurred while fetching data.
Over CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)